Cardiovascular diseases (CVDs) remain a leading cause of morbidity and mortality globally.
Despite significant advancements in the development of pharmacological therapies, the …

Cardiovascular diseases (CVDs) constitute a predominant cause of both global mortality
and morbidity. To address the challenges in the early diagnosis and management of CVDs …

Due to the mortality associated with thrombosis and its high recurrence rate, there is a need
to investigate antithrombotic approaches. Noninvasive site-specific thrombolysis is a current …

Thrombotic diseases have a high rate of mortality and disability, and pose a serious threat to
global public health. Currently, most thrombolytic drugs especially protein drugs have a …

Intravenous injection of thrombolytic drugs is the most feasible strategy for the clinical
treatment of thrombotic diseases, however, its applications are yet limited by narrow …

Undesirable exposures to the nuclear radiation will inevitably cause risks to human health,
and may result in carcinogenesis, organ failure and cell mutations. It is a long-standing and …

Cardiovascular diseases (CVDs), the world's most prominent cause of mortality, continue to
be challenging conditions for patients, physicians, and researchers alike. CVDs comprise a …

Microfluidic technology has emerged as a powerful tool in studying arterial thrombosis,
allowing researchers to construct artificial blood vessels and replicate the hemodynamics of …

Background Thrombolysis is a frontline treatment for stroke, which involves the application of
tissue plasminogen activator (tPA) to trigger endogenous clot‐degradation pathways …

In blood coagulation, circulating platelets and coagulation factors are crucial for the primary
process because thrombi are generated by fibrin clotting with fibrinogen, thrombin, FXIIIa …